In COPD patients receiving LAMA therapy, intracellular Ca2+ signalling is further diminished, which may modulate PDE1A activity and cAMP levels, influencing the net effect on CBF and MCC. Here, PDE1A is linked to chronic obstructive pulmonary disease.